Eli Lilly and Company

Other

Susan Elizabeth Draheim

Nicholas J Bach

Robert D Dillard

Richard Walter Schevitz

Edward David Mihelich

Tulio Suarez

Robert B Hermann

Jason Scott Sawyer

Daniel Jon Sall

Douglas Wade Beight

John Michael Morin, Jr

Ho-Shen Lin

Jolie Anne Bastian

Michael Enrico Richett

Richard Waltz Harper

Michael LeRoy Phillips

Michael Dean Kinnick

Benjamin Alan Anderson

Robert Theodore Vasileff

Michael Lyle Denney

Nancy Kay Harn

Gary A Hite

John Mcneill McGill, Iii

Richard James Loncharich

Robert Delane Dillard

Nicholas James Bach

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of conditions such as septic shock.

Substituted tricyclics

A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of inflammatory diseases such as septic shock.

Indole sPLA2 inhibitors

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.

1H-indole-3-glyoxylamide sPLA2 inhibitors

The present invention relates to methods of treating periodontal disease in a mammal. The methods include administering to an animal an s effective amount of an inhibitor of sPLA,. The inhibitors may be advantageously delivered as a composition that includes various carriers. In certain aspects of the invention, inhibitors used in the method include substituted indole or substituted pyrrole sPLA,inhibitors. Also provided are compositions that include the sPLA,carriers for oral delivery of the inhibitors.

Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2

A class of novel 1H-indole-3-acetamides is disclosed together with the use of such indole compounds for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

1H-indole-3-acetamide sPLA2 inhibitors

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

1H-indole-3-glyoxylamide sPLA.sub.2 inhibitors

Process for preparing 1H-indole-3-glyoxylamides

A class of novel pyrroles is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

Pyrroles as sPLA.sub.2 inhibitors

A class of novel 1-indole-3-acetamides represented by the formula; ##STR1## is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids.

1H-indole-3-acetamide sPLA.sub.2 inhibitors

1H-indole-3-glyoxylamide SPLA.sub.2 inhibitors

A class of novel 1H-indole-1-functional compounds is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock. The compounds are 1H-indole-1-acetamides, 1H-indole-1-acetic acid hydrazides, and 1H-indole-1-glyoxylamides.

1H-indole-1-functional sPLA.sub.2 inhibitors

A class of novel 1H-indole-3-acetic acid hydrazides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids (e.g., arachidonic acid) for treatment of conditions such as septic shock.

Growing community of inventors

Indianapolis, IN, United States of America

Susan Elizabeth Draheim